Search
Chamaecyparis obtusa wood oil
go.drugbank.com/drugs/DB14341InvestigationalChamaecyparis obtusa wood oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Rosa centifolia flower oil
go.drugbank.com/drugs/DB14363InvestigationalRosa centifolia flower oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
CTB001
go.drugbank.com/drugs/DB18316InvestigationalCTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.[L48146]
Azafenidin
go.drugbank.com/drugs/DB19031InvestigationalAzafenidin is under investigation in clinical trial NCT01726582 (Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")).
Synonyms: 2-(2,4-dichloro-5-(2-propynyloxy)phenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyridin-3(2h)-one, 2-(2,4-dichloro-5-prop-2-ynyloxyphenyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyridin-3(2h)-oneRoledumab
go.drugbank.com/drugs/DB16317InvestigationalRoledumab is under investigation in clinical trial NCT02287896 (Pharmacokinetics and Safety of Roledumab in Rhd-negative Pregnant Women Carrying an Rhd-positive Foetus).
Tesnatilimab
go.drugbank.com/drugs/DB16377InvestigationalTesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease).
NY-ESO-1 peptide vaccine
go.drugbank.com/drugs/DB17498InvestigationalNY-ESO-1 peptide vaccine is an investigational cancer immunotherapy. It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).
Linsitinib
go.drugbank.com/drugs/DB06075InvestigationalAn orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.
Practolol
go.drugbank.com/drugs/DB01297ApprovedA beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
EMZ702
go.drugbank.com/drugs/DB05021InvestigationalEMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency